Your Account
Sort
Categories
- #EMSPVirtual2021
- Associate members
- Document
- EMSP Events
- EMSP Events|EMSP News
- EMSP News
- EMSP News|From Europe
- EMSP News|From Europe|Stakeholder Events
- EMSP News|MS Research
- EMSP News|Press Releases
- EMSP News|Young People with MS
- From Europe
- From Europe|Member News
- From Europe|Stakeholder Events
- From Europe|Young People with MS
- Full members
- Full members|Member News
- Member News
- Member News|Young People with MS
- MS Research
- News – EMSP
- Press Releases
- Stakeholder Events
- Uncategorized
- Young People with MS
“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment
The European Commission has granted marketing authorization for Aubagio 14 mg (teriflunomide), an oral therapy recommended for the treatment of…
“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment
The European Commission has granted marketing authorization for Aubagio 14 mg (teriflunomide), an oral therapy recommended for the treatment of…
The Written Declaration bid for neurodegenerative diseases: a useful experience
The bid for a Written Declaration for neurodegenerative diseases (NDDs) in the workplace managed to gather 161 signatures from Members…
Lithuanian MS Union engaged in carrying an innovative and relevant project
Lithuanian MS Union is one of the partners engaged in carrying an innovative and relevant project in Lithuania The Heppy…
Welcome from Maggie Alexander
I’m delighted to be joining the European Multiple Sclerosis Platform (EMSP) at a key stage in the organisation’s development. From…
Welcome from Maggie Alexander
I’m delighted to be joining the European Multiple Sclerosis Platform (EMSP) at a key stage in the organisation’s development. From…
